The effect of the anti-leukemia inhibitory factor on the immune system in the Balb/c mice bearing breast cancer induced with 4T1 cells

[1]  M. Kwak,et al.  Cancer immunotherapy by immune checkpoint blockade and its advanced application using bio-nanomaterials. , 2022, Seminars in cancer biology.

[2]  S. Amanpour,et al.  Down-regulation of immune checkpoints by doxorubicin and carboplatin-containing neoadjuvant regimens in a murine breast cancer model , 2021, Iranian journal of basic medical sciences.

[3]  Shaghayegh Haghjooy Javanmard,et al.  Leukemia inhibitory factor: A main controller of breast cancer , 2020, Journal of biosciences.

[4]  Rachelle W Johnson,et al.  GP130 Cytokines in Breast Cancer and Bone , 2020, Cancers.

[5]  E. Collisson,et al.  Blockade of leukemia inhibitory factor as a therapeutic approach to KRAS driven pancreatic cancer , 2019, Nature Communications.

[6]  A. Pineda-Lucena,et al.  Characterization of triple‐negative breast cancer preclinical models provides functional evidence of metastatic progression , 2019, International journal of cancer.

[7]  Hailin Tang,et al.  Breast cancer subtypes and the risk of distant metastasis at initial diagnosis: a population-based study , 2018, Cancer management and research.

[8]  A. Jemal,et al.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries , 2018, CA: a cancer journal for clinicians.

[9]  Y. Abe,et al.  Landscape of immune microenvironment in hepatocellular carcinoma and its additional impact on histological and molecular classification , 2018, Hepatology.

[10]  M. Oliveira,et al.  Interferon-Gamma at the Crossroads of Tumor Immune Surveillance or Evasion , 2018, Front. Immunol..

[11]  L. Saal,et al.  p53 Maintains Baseline Expression of Multiple Tumor Suppressor Genes , 2017, Molecular Cancer Research.

[12]  Xiao-ming Meng,et al.  TGF-β: the master regulator of fibrosis , 2016, Nature Reviews Nephrology.

[13]  F. Marincola,et al.  Checkpoint Inhibitors and Their Application in Breast Cancer , 2016, Breast Care.

[14]  N. Nicola,et al.  Leukemia inhibitory factor (LIF). , 2015, Cytokine & growth factor reviews.

[15]  K. Young,et al.  LIF negatively regulates tumor suppressor p53 through Stat3/ID1/MDM2 in colorectal cancers , 2014, Nature Communications.

[16]  Zhen Liu,et al.  LIF promotes tumorigenesis and metastasis of breast cancer through the AKT-mTOR pathway , 2014, Oncotarget.

[17]  Graham M Lord,et al.  T-bet: a bridge between innate and adaptive immunity , 2013, Nature Reviews Immunology.

[18]  R. Elledge,et al.  Clinical and biologic features of triple-negative breast cancers in a large cohort of patients with long-term follow-up , 2012, Breast Cancer Research and Treatment.

[19]  K. Ansel,et al.  MicroRNA-29 regulates T-box transcription factors and interferon-γ production in helper T cells. , 2011, Immunity.

[20]  L. Glimcher,et al.  T-bet in disease , 2011, Nature Immunology.

[21]  Frank Speleman,et al.  miR-9, a MYC/MYCN-activated microRNA, regulates E-cadherin and cancer metastasis , 2010, Nature Cell Biology.

[22]  Qiang Zhou,et al.  Treg versus Th17 lymphocyte lineages are cross-regulated by LIF versus IL-6 , 2009, Cell cycle.

[23]  K. Schroder,et al.  Interferon‐γ: an overview of signals, mechanisms and functions , 2004 .

[24]  Fan Zhang,et al.  Down-regulation of caspase 3 in breast cancer: a possible mechanism for chemoresistance , 2002, Oncogene.

[25]  S. Ethier,et al.  Identification of gene expression profiles that predict the aggressive behavior of breast cancer cells. , 2001, Cancer research.

[26]  J. Turkson,et al.  STAT proteins: novel molecular targets for cancer drug discovery , 2000, Oncogene.

[27]  S. Ostrand-Rosenberg,et al.  Mouse 4T1 Breast Tumor Model , 2000, Current protocols in immunology.

[28]  T. Soussi.  The p53 Tumor Suppressor Gene: From Molecular Biology to Clinical Investigation , 2000, Annals of the New York Academy of Sciences.

[29]  H. Lodish,et al.  Role of transforming growth factor beta in human disease. , 2000, The New England journal of medicine.

[30]  G. Hortobagyi,et al.  Expression of leukemia inhibitory factor and its receptor in breast cancer: A potential autocrine and paracrine growth regulatory mechanism , 1998, Breast Cancer Research and Treatment.

[31]  Z. Estrov,et al.  Leukemia‐inhibitory factor stimulates breast, kidney and prostate cancer cell proliferation by paracrine and autocrine pathways , 1996, International journal of cancer.

[32]  D. Goeddel,et al.  Structure of the human immune interferon gene , 1982, Nature.

[33]  J. Krejsek,et al.  Regulatory T cells (TREG) and their roles in immune system with respect to immunopathological disorders. , 2010, Acta medica.

[34]  E. Zepeda-Castilla,et al.  [Molecular classification of breast cancer]. , 2008, Cirugia y cirujanos.

[35]  A. Bamberger,et al.  Differential regulation of the human 'leukemia inhibitory factor' (LIF) promoter in T47D and MDA-MB 231 breast cancer cells , 2004, Breast Cancer Research and Treatment.

[36]  K. Schroder,et al.  Interferon-gamma: an overview of signals, mechanisms and functions. , 2004, Journal of leukocyte biology.

[37]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..

[38]  J. Turkson,et al.  Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. , 1999, Immunity.

[39]  Z. Estrov,et al.  Leukemia inhibitory factor binds to human breast cancer cells and stimulates their proliferation. , 1995, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.